Zhan Ping, Ji Ya-Nan, Yu Li-Ke
1 First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China ; 2 The Collaborative Research (CORE) Group, Sydney, Australia ; 3 Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China.
Transl Androl Urol. 2013 Jun;2(2):99-105. doi: 10.3978/j.issn.2223-4683.2013.06.03.
Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis, and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with prostate cancer, but yielded conflicting results.
Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF status and survival of patients with prostate cancer. Survival data were aggregated and quantitatively analyzed.
We performed a meta-analysis of 9 studies that evaluated the correlation between VEGF overexpression and survival in patients with prostate cancer. Combined hazard ratios suggested VEGF overexpression had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.54, 95% CI (confidence interval): 1.25-1.83], but not disease free survival (DFS) (HR=1.23, 95% CI: 0.99-1.47) in patients with prostate cancer. No significant heterogeneity was observed among all studies.
VEGF overexpression indicates a poor prognosis for patients with prostate cancer.
血管内皮生长因子（VEGF）被认为是血管生成的主要介质，并与癌症发生和转移有关。多项研究探讨了前列腺癌患者VEGF过表达与临床结局之间的关系，但结果相互矛盾。
检索截至2013年7月更新的电子数据库以查找相关研究。对符合条件的研究进行荟萃分析，这些研究定量评估了VEGF状态与前列腺癌患者生存之间的关系。汇总生存数据并进行定量分析。
我们对9项评估前列腺癌患者VEGF过表达与生存相关性的研究进行了荟萃分析。合并风险比表明，VEGF过表达对前列腺癌患者的总生存期（OS）有不利影响[风险比（HR）=1.54，95%置信区间（CI）：1.25 - 1.83]，但对无病生存期（DFS）无影响（HR = 1.23，95% CI：0.99 - 1.47）。所有研究中未观察到显著的异质性。
VEGF过表达表明前列腺癌患者预后不良。
